If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00453440","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK population. HLA-B*5701 has been strongly associated with the risk of an allergic reaction to a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction. The study is a prospective study inviting HIV-1 positive patients over the age of 18 years to participate. Each participant will complete one study visit. They will be asked for details of their background including their age, sex, ethnicity, country of origin and parental country of origin. They will be asked to give two samples to test for the presence of the genetic marker HLA-B*5701. The two samples are: - A cheek swab - A blood sample In selected centres patients may be asked to provide up to two additional blood samples. These samples will be used to help develop and validate new methods of determining HLA-B*5701 testing.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:34:28","criteria":"Inclusion criteria: - HIV-1 infected patients over 18 years of age - Patient willing & able to understand and provide written informed consent Exclusion criteria: - None","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"","display_phase_internal":"","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"1502","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"062f673d-6a9b-5747-8de2-be0324348955","internal":{"content":null,"contentDigest":"d9c300d8d8685db03c79ebb13723d056","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria: - HIV-1 infected patients over 18 years of age - Patient willing & able to understand and provide written informed consent Exclusion criteria: - None","interventions":[{"arm_group_label":"","intervention_description":"Cheek swab & blood test","intervention_name":"Cheek swab & blood test","intervention_type":"Procedure/Surgery"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["HIV","HLA-B*5701","Abacavir hypersensitivity reaction","HIV Infection"],"last_follow_up_date":"08/10/2007 00:00:00","links":[],"locations":[{"City":"Birmingham","Latitude":"52.4845468","CountryDisplay":"United Kingdom","Longitude":"-1.8952293","Name":"GSK Investigational Site","StateDisplay":"Warwickshire","PostalCode":"B4 6DH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.426561","CountryDisplay":"United Kingdom","Longitude":"-0.1760824","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SW17 0QT","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.550818","CountryDisplay":"United Kingdom","Longitude":"-0.0459012","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"E9 6SR","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5190259","CountryDisplay":"United Kingdom","Longitude":"-0.058075","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"E1 1BB","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Woolwich, London","Latitude":"51.4775553","CountryDisplay":"United Kingdom","Longitude":"0.0505446","Name":"GSK Investigational Site","StateDisplay":"London","PostalCode":"SE18 4QH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4985226","CountryDisplay":"United Kingdom","Longitude":"-0.1195779","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SE1 7EH","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5170141","CountryDisplay":"United Kingdom","Longitude":"-0.1742622","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"W2 1NY","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Birmingham","Latitude":"52.5827581","CountryDisplay":"United Kingdom","Longitude":"-1.9987338","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"WS2 9PS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 23:02:50","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"1","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Prospective epidemiological study of the prevalence of HLA-B*5701 in HIV-1 infected UK patients","org_study_id":"CNA109479","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"","primary_compl_date":"08/10/2007 00:00:00","primary_outcomes":[{"outcome_description":"The widespread of HLA-B*5701 applied in the selected area in each participant of the UK population was tested via central labs. The result is summarized here.","outcome_measure":"Prevalence of HLA-B*5701 in the UK population via central labs","outcome_time_frame":"2 Hours","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Prevalence of HLA-B*5701 in major UK ethnotypes in the study population.","outcome_time_frame":"2 Hours","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Description of HLA-B*5701 in the UK population via local labs.","outcome_time_frame":"2 Hours","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GSK"]},"start_date":"03/20/2007 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"CNA109479"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}